-5%
Resmetirom is a selective, partial agonist of thyroid hormone receptor-beta (THR-β). In vitro studies demonstrate that Resmetirom produces 83.8% of the maximal response of triiodothyronine (T3) at THR-β, with an EC₅₀ of 0.21 μM. Its activity at thyroid hormone receptor-alpha (THR-α) is lower, showing 48.6% efficacy relative to T3, with an EC₅₀ of 3.74 pM.
THR-β is the predominant thyroid hormone receptor in the liver, and its activation leads to a reduction in intrahepatic triglyceride levels, thereby improving liver fat metabolism.
TRB tablet is indicated, along with an appropriate diet and regular exercise, for the treatment of adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) who have moderate to advanced liver fibrosis (fibrosis stages F2–F3).